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Development of drug resistance in a human epidermoid lung carcinoma
xenograft line
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Summary The development of resistance to vincristine, actinomycin D and cisplatin has been examined in a
human epidermoid lung carcinoma xenograft line (HXL 55) growing in nude mice. Treatment of HXL 55 with
1 mgkg- 1 vincristine or 0.5 mgkg-1 actinomycin D once in each in vivo passage resulted in a rapid reduction
in tumour responsiveness to these drugs. A partial resistance was already acquired at the 2nd transplant
generation. In contrast, a gradual decrease in therapeutic response was observed with 10 mgkg 1 cisplatin.
Irradiation with a local dose of 10Gy induced no resistance. The three induced drug-resistant sublines were
characterized in terms of the time course of development of resistance, the degree of induced resistance, cross-
resistance, growth rate and stability of the phenotype.
The development of resistance to chemotherapy is a major
problem in the treatment of cancer. Tumours which are
initially responsive to chemotherapy can develop resistance
during treatment with cytotoxic agents. Clinically, this is
characterized by short periods of remission and failure to
respond to subsequent therapy. For many drugs, the mecha-
nism for resistance is unknown, and it may depend on the
origin of the cell, the degree of resistance, and the method
by which resistance was selected (Houghton et al., 1985).
While a number of investigators have selected sublines of
murine and human tumours in vitro which are resistant to
various drugs by repeated exposure of the target cells to a
sublethal concentration of drug (Conter & Beck, 1984;
Twentyman et al., 1986; Tsuruo et al., 1986), there are only
few studies of the rate at which resistance develops during in
vivo treatment (Griswold et al., 1974; Schabel et al., 1978;
McMillan et al., 1985). Repeated treatments at high doses in
vivo mimic the clinical situation better and may prove more
applicable for the investigation of the mechanisms of
resistance.
In the present study, therefore, we have investigated the
development of resistance to high doses of vincristine,
actinomycin D and cisplatin in a human epidermoid lung
carcinoma line growing as a xenograft in nude mice. In
addition to the purpose to develop resistance to the three
cytotoxic agents, the parent line was also treated with
repeated doses of irradiation in order to develop a further
resistant subline.
Materials and methods
Nude mice
NMRI (nu/nu) female mice, 6-10 weeks old, were purchased
from the Breeding Center, Hannover, FRG. The animals
were maintained by conventional methods in Makrolon
cages at 25°C and 50% humidity. Autoclaved feed and
acidified water were provided ad libitum.
Tumour
Tumour HXL 55 was established directly as a xenograft
from an epidermoid lung carcinoma resected in a 49 year old
man (Mattern et al., 1985). The donor had a tumour with a
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diameter of 8 cm in the left upper lobe, staged postopera-
tively as T3NIMO. Since the patient had not received any
therapy, the disease progressed rapidly and he died 6 months
after operation. Histologically, the human biopsy specimen
and who corresponding xenograft in all passages fulfilled the
WHO criteria of a poorly differentiated epidermoid lung
carcinoma. Cytogenetic studies revealed a human karyotype.
The detailed histology, tumour markers and general chemo-
therapeutic sensitivity of HXL 55 are described elsewhere
(Mattern et al., 1987; Bak et al., 1987).
Development of drug resistance
In order to develop drug resistance, the human epidermoid
lung carcinoma line HXL 55 was treated in consecutive
passages with single doses of 1 mgkg-1 vincristine,
0.5 mgkg-1 actinomycin D or 10 mgkg-1 cisplatin and
growth delay was measured. At each tumour passage, the
first treated tumour to regrow was passaged into 8-14 fresh
mice. Of these mice half were treated and half served as
controls. This procedure was repeated eight times.
Evaluation of therapeutic effect
For cross-resistance studies the tumour-bearing mice were
randomized into groups of 5-7 animals each. After the
tumours reached a mean diameter of 8-10 mm, treatment
with the drugs (as single i.p. dose) or irradiation was started.
Each drug was given at the maximum-tolerated dose to the
mouse. Vincristine (VCR, Eli Lilly GmbH, Bad Homburg):
2 mgkg-1; actinomycin D (AD, MSD Sharp & Dohme,
GmbH, Miinchen): 0.5mgkg-1; adriamycin (ADM, Farmi-
talia Carlo Erba GmbH, Freiburg); 10mgkg-1; cisplatin
(DDP, Bristol-Myers GmbH, Neu-Isenburg): 10mgkg-1;
cyclophosphamide (CTX, Asta-Werka Degussa, Bielefeld):
240mgkg- 1.
All agents were injected in a volume of 0.02 mlg 1 body
wt. Photon irradiation was performed with Co60 gamma
rays (Siemens, Erlangen). Dose: 10 Gy. The tumour growth
was followed by measuring two diameters daily with calipers.
The tumour weight was calculated by the formula (a2 x b)/2
where b was the largest diameter and a was the diameter
perpendicular to b. Growth curves were plotted and the time
taken for treated and control groups to double in volume
was obtained. Tumour growth delay was calculated as the
difference between these values. When divided by the control
doubling time, it yields an estimate termed specific growth
delay (Kopper & Steel, 1975). This value can be regarded as
the number of volume doubling times by which treatment
delays tumours growth.
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Flow cytometric analysis
The xenografted tumours were dispersed into single cell
suspensions and fixed in methanol. Preparation and DNA-
analysis were performed as previously described (Volm et al.,
1987), using a flow cytofluorometer (ICP 22, Phywe).
Statistical analysis
Wilcoxon rank sum test was used to compare control groups
versus treated groups.
Results
Selection of drug resistant sublines
Figure 1 shows the changes in growth delay produced by
repeated drug treatments with each drug. With 1 mgkg 1
vincristine and 0.5mgkg-1 actinomycinD, resistance was
acquired already at the 2nd transplant generation, i.e. the
administration of a single dose was able to induce a partial
resistance which could not be further increased by additional
in vivo treatments. The growth delay (GD) dropped from 7.2
to 2.8 days for vincristine, with a reduction factor of 2.6
(GD in untreated tumour/GD in treated tumour) after 8
treatments and from 8.0 to 2.3 days for actinomycin D with
a factor of 3.5 after 8 passages. Eight treatments with
10mgkg-1 cisplatin reduced the growth delay from 10.9 to
5.4 days, a factor of 2.0. The growth delays for zero
previous treatments were constant during the development of
resistance (data not shown). In comparison to that with
10
8
6 -
4
2
>13
VCR
8-
6-
4-
2-
n
0 2 4 6 8
vincristine or actinomycin D, resistance to cisplatin deve-
loped gradually and was still incomplete after 8 treatments.
Irradiation with a local dose of 1OGy produced no signifi-
cant change in growth delay after 7 treatments.
Tumour growth rate
There were no statistically significant differences in tumour
volume doubling times between the parent line HXL 55:
3.8 +0.4 days (mean +s.d.) and the resistant sublines
HXL 55/VCR: 4.0+0.5 days; HXL 55/AD: 3.9+0.3 days;
HXL 55/DDP: 4.0+0.4 days.
Stability of drug resistance
The specific growth delays produced by I mgkg 1 vincristine
in HXL 55/VCR, 0.5 mgkg-1 actinomycin D in HXL 55/AD
or 10 mgkg-1 cisplatin in HXL 55/DDP did not change
significantly after 5 untreated passages (Table I).
Table I Stability of drug resistance after cessation of
drug treatment
Resistant sublines Specific growth delay
1st passagea 5th passageb
HXL 55/VCR 0.7+0.3c 0.5+0.1 NSd
HXL 55/AD 0.6+0.2 0.5+0.3 NS
HXL 55/DDP 1.5+0.3 1.3+0.4 NS
aAfter 8 previous treatments; bAfter 5 passages without
treatment; cMean +s.d.; dNot significant.
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Figure 1 Development of drug resistance in a human epidermoid lung carcinoma xenograft line growing in nude mice. Growth
delay produced by given doses during repeated treatment with mgkg-I vincristine (VCR); 0.5mgkg-1 actinomycin D (AD);
10 mgkg- 1 cisplatin (DDP); 10 Gy of local photon irradiation (Co60). The points with the bars represent mean values + s.d. of 4-7
animals.
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Cross resistance studies
Cross resistance patterns in vivo for the sensitive parent line
and the drug-resistant sublines after 8 treatments are shown
in Table II. With the vincristine-resistant subline (HXL 55/
VCR), cross-resistance between actinomycin D and adriamy-
cin is apparent. The values are significantly different from
the parent line (P_0.05). No change in sensitivity was
observed with cyclophosphamide, cisplatin or irradiation.
The actinomycin D-resistant subline (HXL 55/AD) showed a
decreased sensitivity to vincristine (significant) and only a
slight decreased sensitivity to adriamycin (not significant).
With this tumour line, also a decreased sensitivity to cyclo-
phosphamide and a slight increased sensitivity to cisplatin
was found (not significant). No change in sensitivity to
irradiation was observed. The cisplatin-resistant subline
(HXL 55/DDP) showed statistically significant resistance not
only to cisplatin, but also to vincristine, actinomycinD and
adriamycin and to a lesser degree to cyclophosphamide and
irradiation (not significant).
Flow cytometric analyses
The DNA distribution of all sublines was indistinguishable
from the parent sensitive line when analysed by flow cyto-
metry (data not shown). Only one aneuploid population
could be detected in all lines. DNA analyses performed in
each transplant generation did not show any significant
variations in the tumours.
Discussion
In experimental cancer chemotherapy, the precise kinetics of
emergence of cytotoxic drug resistance during treatment of
tumours in vivo have not been widely explored. In most
studies, drug resistance was developed through multiple
subcurative doses which were gradually increased in subse-
quent transfer generations. However, with this method the
kinetics of resistance development cannot be adequately
studied. Since in the clinic the patients are normally treated
with high doses of antitumour agents, repeated treatments at
optimal therapeutic doses in animals mimic the clinical
situation better and may prove, therefore, more applicable
for the investigation of the development of resistance.
In the present study, we investigated the development of
resistance to three commonly used antitumour agents (vin-
cristine, actinomycin D and cisplatin) at high doses in a
chemosensitive human epidermoid lung carcinoma xenograft
line. All three drugs are normally given as single agents or as
components of multi-agent therapy regimens in the clinic.
We found that repeated high dose drug treatment resulted in
a reduction in tumour response as assayed by growth delay
in vivo. The degree of resistance achieved and the time course
of its development varied according to the drug used. For
example, the growth delay induced by 8 treatments of
1 mgkg1 vincristine was reduced by a factor of 2.6, while
the growth delay, induced by 0.5 mgkg- actinomycin D or
10mgkg-1 cisplatin was 3.5 or 2.0 respectively. The devel-
opment of resistance was unexpectedly rapid following treat-
ment with vincristine and antinomycin D. With these two
drugs partial resistance was observed already at the 2nd
transplant generation. This fact indicates that a resistant cell
population was selected by only a single treatment in the 1st
transplant generation. Similar results were reported by
Houghton et al. (1985). They exposed a human childhood
rhabdomyosarcoma grown as a xenograft in immune-
deprived mice to a single dose of 3 mgkg-1 vincristine and
found that with this single administration a 4-fold resistance
to vincristine was induced which was stable for prolonged
periods in the absence of the drug.
On the other hand, sensitivity of HXL 55 to cisplatin was
gradually lost by repeated drug treatment and resistance was
still incomplete after 8 transplant generations. These results
are consistent with other previously published studies in
which a gradual decrease in therapeutic response was
detected during repeated drug treatment with cisplatin
(McMillan et al., 1985; Osieka & Schmidt, 1982). Alkylating
agents as well as nitrosoureas also induce a stepwise pattern
of resistance development (Griswold et al., 1974; Schabel,
1976, 1978; Osieka & Schmidt, 1982; Berman & Steel, 1984;
McMillan et al., 1985, 1987; Schmid et al., 1986).
It is interesting to note that in bacterial chemotherapy
resistance to different drugs develops also in discrete steps,
and that a high degree of resistance may either build up
through successive changes or be attained in a one-step
change. The pattern followed is characteristic for any parti-
cular drug. Two patterns have been recognized: the so-called
'penicillin' pattern, in which high resistance is reached only
through multi-step changes; and the 'streptomycin' pattern,
in which high resistance may arise in a single step (Demerec,
1957). It is also noteworthy that the resistance pattern to a
certain drug follows the same pattern in all strains and
species of bacteria (Demerec, 1955) or in all tumour lines
independent of animal or human origin. It still remains
uncertain whether the drug-resistant sublines are established
by mutation or by selection of resistant cells pre-existing in
the original cell population. The rapid rate at which resis-
tance e.g. to vincristine or actinomycin D developed sug-
gested that a pre-existent subpopulation resistant
to these agents was present in the original tumour.
The importance of growth kinetics of tumours for resis-
tance to chemotherapy is well known (for review see Steel,
1977). An analysis of the growth rate of the tumours
indicated that resistance to the three drugs used in this study
was not due to changes in the growth rate during drug
treatment. This is in agreement with some studies which
found no gross difference in growth rate between the parent
line and the resistant sublines (Skovsgaard, 1975; McMillan
et al., 1985; Bence et al., 1986). This is in contrast to the
report by Dan0 (1972).
In our study the induced drug resistance phenotype
remained fairly stable over 5 generations of in vivo passages
in the absence of anticancer agents. How far these data,
however, demonstrate perhaps a genetic rather than a epi-
genetic aetiology has to be proven.
The knowledge of patterns of cross-resistance and colla-
teral sensitivity is valuable in the scheduling of antitumour
agents and in designing optimal drug combinations. The
Table II Cross-resistance studies of the sensitive parent line HXL 55 and the resistant sublines
Specific growth delay
Drug HXL 55 HXL55/VCR Rja HXL55/AD RI HXL55/DDP RI
Vincristine 4.3+0.2b 1.2+0.3c 3.6 2.3+l,OC 1.9 2.2+0.2C 2.0
Actinomycin D 1.9+0.2 0.5+0.1C 3.8 0.6+0.3c 3.2 0.9+0.7C 2.1
Adriamycin 0.9+0.2 0.2+0.1c 4.5 0.8+0.5 1.1 0.5+0.1C 1.8
Cyclophosphamide 2.2+0.8 2.3+0.5 1.0 1.7+0.5 1.3 1.5+0.6 1.5
Cisplatin 2.6+0.5 2.3+0.3 1.1 3.0+0.7 0.9 1.5+0.3c 1.7
Co60 3.3+1.6 3.3+1.0 1.0 3.4+1.1 1.0 2.8+1.3 1.2
aRelative index of resistance (RI) was calculated as the ratio of specific growth delay in the
resistant lines (HXL 55/VCR; HXL 55/AD; HXL 55/DDP) and in the sensitive parent line (HXL 55);
bMean +s.d.; cSignificantly different from the parent line HXL55 (P<0.05).DRUG RESISTANCE IN EPIDERMOID LUNG CANCER XENOGRAFT 33
data (Table II) indicate that the three resistant sublines
display different degrees of resistance and cross-resistance.
While HXL 55/VCR shows the known multidrug-resistant
phenotype with cross-resistance to actinomycin D and no
change in sensitivity to cyclophosphamide or cisplatin or
irradiation, the line HXL 55/AD shows only a significant
cross-resistance to vincristine and a slight decreased sensiti-
vity to adriamycin. Similar results were found by Schabel et
al. (1980). They described an antinomycin D-resistant line of
the P 388 leukaemia which showed no cross-resistance to
adriamycin. In contrast to HXL55/VCR and HXL55/AD,
the line HXL55/DDP showed cross-resistance to all drugs
tested. Conter & Beck (1984) have shown that each cell line
displays individual patterns of resistance and cross resis-
tance, regardless of the selecting agent. Furthermore, com-
parable degrees of resistance to one drug do not necessarily
predict comparable degrees of cross-resistance to other
drugs.
In conclusion, our data presented here show that a rapid
development of resistance with vincristine and actinomycin D
occurs whereas a gradual decrease in therapeutic response is
achieved by repeated drug treatment with cisplatin. Each cell
line displays an individual, not predictable pattern of cross-
resistance. Therefore, we believe that a knowledge of the
emergence of drug resistance and cross-resistance could
provide information for optimal drug scheduling as well as
data indicating which particular drugs should be excluded
from combinations or sequential therapy schedules.
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